Skip to main content
Journal cover image

Current status of percutaneous PFO closure.

Publication ,  Journal Article
Rohrhoff, N; Vavalle, JP; Halim, S; Kiefer, TL; Harrison, JK
Published in: Curr Cardiol Rep
May 2014

The clinical significance of persistent patent foramen ovale (PFO) is not well defined. Empirically, PFO has been associated with many clinical conditions. In cryptogenic stroke, migraine, and orthodeoxia/platypnea, a plausible biologic mechanism exists to support PFO closure as a possible treatment. Although transcatheter closure of PFO has been available for over 2 decades, it has remained controversial due to a paucity of evidence to guide patient and device selection. Contemporary studies investigating PFO closure as treatment for patients with these conditions have been published recently and longitudinal data regarding the safety and efficacy of the devices is now available. In this review, we aim to describe the potential clinical significance of a patent foramen in the adult, appraise the newest additions to the body of evidence, and discuss the safety, benefit, patient selection, and future of transcatheter treatment of PFO.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Curr Cardiol Rep

DOI

EISSN

1534-3170

Publication Date

May 2014

Volume

16

Issue

5

Start / End Page

477

Location

United States

Related Subject Headings

  • Treatment Outcome
  • Thrombolytic Therapy
  • Survival Rate
  • Stroke
  • Septal Occluder Device
  • Risk Factors
  • Risk Assessment
  • Practice Guidelines as Topic
  • Patient Selection
  • Migraine Disorders
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Rohrhoff, N., Vavalle, J. P., Halim, S., Kiefer, T. L., & Harrison, J. K. (2014). Current status of percutaneous PFO closure. Curr Cardiol Rep, 16(5), 477. https://doi.org/10.1007/s11886-014-0477-4
Rohrhoff, N., J. P. Vavalle, S. Halim, T. L. Kiefer, and J. K. Harrison. “Current status of percutaneous PFO closure.Curr Cardiol Rep 16, no. 5 (May 2014): 477. https://doi.org/10.1007/s11886-014-0477-4.
Rohrhoff N, Vavalle JP, Halim S, Kiefer TL, Harrison JK. Current status of percutaneous PFO closure. Curr Cardiol Rep. 2014 May;16(5):477.
Rohrhoff, N., et al. “Current status of percutaneous PFO closure.Curr Cardiol Rep, vol. 16, no. 5, May 2014, p. 477. Pubmed, doi:10.1007/s11886-014-0477-4.
Rohrhoff N, Vavalle JP, Halim S, Kiefer TL, Harrison JK. Current status of percutaneous PFO closure. Curr Cardiol Rep. 2014 May;16(5):477.
Journal cover image

Published In

Curr Cardiol Rep

DOI

EISSN

1534-3170

Publication Date

May 2014

Volume

16

Issue

5

Start / End Page

477

Location

United States

Related Subject Headings

  • Treatment Outcome
  • Thrombolytic Therapy
  • Survival Rate
  • Stroke
  • Septal Occluder Device
  • Risk Factors
  • Risk Assessment
  • Practice Guidelines as Topic
  • Patient Selection
  • Migraine Disorders